Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

1.

Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.

Chu PG, Loera S, Huang Q, Weiss LM.

Am J Clin Pathol. 2006 Oct;126(4):534-44.

PMID:
16938666
2.

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.

Clarke LE, Bayerl MG, Ehmann WC, Helm KF.

J Cutan Pathol. 2003 Aug;30(7):459-62.

PMID:
12859745
3.

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.

Ann Hematol. 2003 Sep;82(9):585-8.

PMID:
12898184
4.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x.

5.

Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases.

Oliveira JL, Grogg KL, Macon WR, Dogan A, Feldman AL.

Am J Surg Pathol. 2012 Sep;36(9):1364-70. doi: 10.1097/PAS.0b013e31825e63a9.

PMID:
22895269
6.

Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.

Chu PG, Chen YY, Molina A, Arber DA, Weiss LM.

Leuk Lymphoma. 2002 Dec;43(12):2335-41.

PMID:
12613521
7.

[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].

Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y.

Ai Zheng. 2007 Apr;26(4):418-22. Chinese.

PMID:
17430665
8.

Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.

Blakolmer K, Vesely M, Kummer JA, Jurecka W, Mannhalter C, Chott A.

Mod Pathol. 2000 Jul;13(7):766-72.

9.
10.

Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: histology, immunophenotype, and differential diagnosis.

Dogan A, Burke JS, Goteri G, Stitson RN, Wotherspoon AC, Isaacson PG.

Am J Surg Pathol. 2003 Jul;27(7):903-11.

PMID:
12826882
11.

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.

Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.

J Cutan Pathol. 2005 Oct;32(9):616-21.

PMID:
16176299
12.

Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.

Colomo L, Loong F, Rives S, Pittaluga S, Martínez A, López-Guillermo A, Ojanguren J, Romagosa V, Jaffe ES, Campo E.

Am J Surg Pathol. 2004 Jun;28(6):736-47.

PMID:
15166665
13.

Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody.

Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, Tsukada N, Takizawa J, Aoki S, Kojima M, Nakamura S, Kobata T.

Virchows Arch. 2005 Jul;447(1):53-60.

PMID:
16025281
14.

CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.

Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S.

Am J Surg Pathol. 2005 Oct;29(10):1399-403.

PMID:
16160485
15.

Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion.

Hoeller S, Tzankov A, Feichter G, Obermann E, Dirnhofer S.

Cytopathology. 2009 Aug;20(4):273-4. doi: 10.1111/j.1365-2303.2008.00616.x. No abstract available.

PMID:
19207312
16.
17.

[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].

Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.

Rinsho Ketsueki. 2004 Oct;45(10):1129-34. Japanese.

PMID:
15553050
18.

Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.

Kanavaros P, Gaulard P, Charlotte F, Martin N, Ducos C, Lebezu M, Mason DY.

Am J Pathol. 1995 Mar;146(3):735-41.

19.

Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.

Yao X, Teruya-Feldstein J, Raffeld M, Sorbara L, Jaffe ES.

Mod Pathol. 2001 Feb;14(2):105-10.

20.

Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.

Wilkerson MJ, Dolce K, Koopman T, Shuman W, Chun R, Garrett L, Barber L, Avery A.

Vet Immunol Immunopathol. 2005 Jul 15;106(3-4):179-96.

PMID:
15963817

Supplemental Content

Support Center